Enregistrement :
14
de
31
(2017-09-01
à
2017-11-03)
Politique ou Programme
Common Drug Review, importance of meaningful public/patient input into the drug review process
Encouraging the development of a rare disease strategy in Canada (similar to the policies for rare diseases in Europe and the United States).
With respect to Health, we advocate for access to cystic fibrosis (CF) medicines and treatments, the development of a rare disease strategy, and for improved access to disability supports for people with CF. This includes any funding required to support the development and implementation of these policy and legislative proposals. The exact amount of funding has yet to be established and would involve further discussions with government officials.
Politique ou Programme, Règlement
Health Canada with respect to the regulation of pancreatic enzymes used in the management of cystic fibrosis. Recommend product should be listed on Schedule F to the Food and Drugs Regulations.
Politique ou Programme, Subvention, Contribution ou autre avantage financier
In terms of research and development, we lobby for support of cystic fibrosis research initiatives that improve the health and wellness of Canadians living with cystic fibrosis.
In terms of science and technology, we work toward the development of precision and personalized medicines that target the basic defect of cystic fibrosis. We are exploring how the federal government may support these efforts through partnership and funding.
Increased federal investment in health-related research. We worked with the Health Charities Coalition of Canada (HCCC) to draft content for a press release urging the federal government to invest more in basic science in Canada.
Proposition législative, Projet de loi ou résolution
Advocated for Bill S-201, An Act to Prohibit and Prevent Genetic Discrimination. This Bill received Royal Assent on May 4, 2017.